Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany

References

• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Dignass AU, Atreya R, et al. Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Z Gastroenterol. 2019;57:162–241.
   PubMed Web of Science ®Google Scholar
• Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113–120.
   PubMedGoogle Scholar
• Mowat C, Cole A, Windsor A, et al. IBD Section of the British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
   PubMed Web of Science ®Google Scholar
• Prenzler A, Bokemeyer B, Mittendorf T, et al. [Costs of ulcerative colitis within the German Statutory Health Insurance]. Dtsch Med Wochenschr. 2010;135:281–286.
   PubMed Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al., European Crohn’s and Colitis Organisation [ECCO]. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769–784.
   PubMed Web of Science ®Google Scholar
• Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010;4:355–366.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30.
   PubMed Web of Science ®Google Scholar
• Garcia-Bosch O, Gisbert JP, Canas-Ventura A, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013;7:717–722.
   PubMed Web of Science ®Google Scholar
• Janssen. Product monograph: remicade; infliximab: powder for solution. 2017. Available from: http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/remicade_cpm.pdf
   Google Scholar
• Janssen. Product monograph: simponi (golimumab): solution for injection. 2017. Available from: http://www.janssen.com/canada/sites/www_janssen_com_canada/files/prod_files/live/simponi_cpm.pdf
   Google Scholar
• Lowenberg M, D'Haens G. Next-generation therapeutics for IBD. Curr Gastroenterol Rep. 2015;17:21.
   PubMedGoogle Scholar
• Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9:18–27.
   PubMed Web of Science ®Google Scholar
• Takeda. Product monograph: entyvio (vedolizumab). 2016. Available from: https://www.takeda.com/4a5b27/siteassets/en-ca/home/what-we-do/our-medicines/product-monographs/entyvio/entyvio-pm-en.pdf/
   Google Scholar
• European Medicines Agency. Xeljanz. EPAR - product information. 2019.
   Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Remicade. EPAR – product information. 2009. Available from: https://www.ema.europa.eu/en/documents/product-information/remicade-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Humira. EPAR – product information. 2008. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Simponi. EPAR – product information. 2014. Available from: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. Entyvio. EPAR – product information. 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/entyvio-epar-product-information_en.pdf
   Google Scholar
• European Medicines Agency. ANNEX I. Summary of product characteristics. European Medicines Agency.
   Google Scholar
• Dignass A, Waller J, Cappelleri JC, et al. P782 Living with ulcerative colitis in Germany: quantifying the healthcare resource utilisation and direct healthcare costs associated with the treatment of moderate to severe ulcerative colitis in Germany. J Crohns Colitis. 2019;13:S512.
   Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Targeted immune modulators for ulcerative colitis: effectiveness and value; draft evidence report 2020. 2020. Available from: https://icer.org/wp-content/uploads/2020/08/ICER_UC_Evidence_Report_091120-002.pdf
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Common drug review: pharmacoeconomic review report – vedolizumab (Entyvio®). 2015 [cited 2020]. Available from: https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0421_Entyvio_PE_Report.pdf
   Google Scholar
• Stawowczyk E, Kawalec P. A systematic review of the cost-effectiveness of biologics for ulcerative colitis. Pharmacoeconomics. 2018;36:419–434.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Ng SC, Lakatos PL, et al. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis. 2013;19:1–10.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Mortality and global health estimates. Life table by country: Canada. 2015. Available from: http://apps.who.int/gho/data/?theme=main&vid=60290
   Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33:607–617.
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. National Institute for Health and Care Excellence; 2014.
   Google Scholar
• Thorlund K, Druyts E, Toor K, et al. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015;9:693–700.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265.e1–3.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:96–109.e1.
   PubMed Web of Science ®Google Scholar
• Tappenden P, Ren S, Archer R, et al. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics. 2016;34:1023–1038.
   PubMed Web of Science ®Google Scholar
• Xie F, Blackhouse G, Assasi N, et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc. 2009;7:20.
   PubMedGoogle Scholar
• Targownik LE, Singh H, Nugent Z, et al. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228–1235.
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr, Delgado DJ, Friedman HS, et al. Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol. 2008;103:1737–1745.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Panes J, Sands BE, et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019;50:1068–1076.
   PubMed Web of Science ®Google Scholar
• Pfizer. Adhoc analysis of OCTAVE Sustain (1096 DB Maintenance); Data on file: study report output for PRJA392 submission (ibd_pub) Protocol(SCSA3920202a).
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Golimumab (Simponi), Pharmacoeconomic Review. 2014.
   Google Scholar
• National Institute for Health and Care Excellence. Vedolizumab (Entyvio®) for the treatment of adults with moderate to severe active ulcerative colitis. Single technology appraisal (STA) 2014. Available from: https://www.nice.org.uk/guidance/ta342/documents/ulcerative-colitis-moderate-to-severely-active-vedolizumab-id691-evaluation-report-part-22
   Google Scholar
• National Association of Statutory Health Insurance Physicians (Kassenärztliche Bundesvereinigung). 2019 [cited May 2020]. Available from: https://www.kbv.de/html/
   Google Scholar
• Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731–1736.
   PubMed Web of Science ®Google Scholar
• Lauer-Fischer GmbH. The Lauer-Taxe download [Database]. 2020. Available from: https://www.cgm.com/lauer-fischer/loesungen_lf/lauer_taxe_lf/lauer_taxe_download_lf/lauer_taxe_download_en.de.jsp
   Google Scholar
• Kassenarztliche Bundesvereinigung (KBV). 13391 - Grundpauschale 6.- 59. Lebensjahr. 2019.
   Google Scholar
• Ebinger M, Leidl R, Thomas S, et al. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol. 2004;19:192–199.
   PubMed Web of Science ®Google Scholar
• Haas C, Larbig M, Schöpke T, et al. Gutachten zur ambulanten Notfallversorgung im Krankenhaus - Fallkostenkalkulation und Strukturanalyse. 2015. Available from: https://www.kgrp.de/uploads/download/2015-02-17_Gutachten_zur_ambulanten_Notfallversorgung_im_Krankenhaus_2015.pdf
   Google Scholar
• Wu B, Wang Z, Zhang Q. Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2018;24:2291–2302.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Bergman A, Chevrou-Severac H, et al. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2018;19:229–240.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH). Common drug review: vedolizumab (Entyvio®) in ulcerative colitis, notice of final recommendation. 2015.
   Google Scholar
• National Institute for Health and Care Excellence. Tofacitinib for previously treated active ulcerative colitis [ID1218] In Single Technology Appraisal. 2018.
   Google Scholar
• Stern S, Ward AJ, Saint-Laurent Thibault C, et al. Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation. J Med Econ. 2018;21:27–37.
   PubMed Web of Science ®Google Scholar
• Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol. 2016;3:e000093.
   PubMed Web of Science ®Google Scholar
• Thorlund K, Druyts E, Toor K, et al. Incorporating alternative design clinical trials in network meta-analyses. Clin Epidemiol. 2015;7:29–35.
   PubMed Web of Science ®Google Scholar